The historical rank and industry rank for Fisher & Paykel Healthcare's Cyclically Adjusted Price-to-FCF or its related term are showing as below:
FRA:FPLB'
s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 60.89 Med: 98.91 Max: 235.5
Current: 126.54
During the past 13 years, Fisher & Paykel Healthcare's highest Cyclically Adjusted Price-to-FCF was 235.50. The lowest was 60.89. And the median was 98.91.
FRA:FPLB's Cyclically Adjusted Price-to-FCF is ranked worse than 85.45% of 220
companies
in the Medical Devices & Instruments industry
Industry Median: 47.755
vs FRA:FPLB: 126.54
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.
Fisher & Paykel Healthcare's adjusted free cash flow per share data of for the fiscal year that ended in Mar24 was €0.086. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is €0.16 for the trailing ten years ended in Mar24.
Shiller PE for Stocks: The True Measure of Stock Valuation
Fisher & Paykel Healthcare Cyclically Adjusted Price-to-FCF Historical Data
The historical data trend for Fisher & Paykel Healthcare's Cyclically Adjusted Price-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Fisher & Paykel Healthcare's Cyclically Adjusted Price-to-FCF
For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fisher & Paykel Healthcare's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Fisher & Paykel Healthcare's Cyclically Adjusted Price-to-FCF falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.
Fisher & Paykel Healthcare Cyclically Adjusted Price-to-FCF Related Terms
Thank you for viewing the detailed overview of Fisher & Paykel Healthcare's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use humidifiers, masks and related consumables and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns 42% of its revenue in the US, 32% in Europe, 18% in Asia-Pacific and the remaining 8% in emerging markets. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand and Mexico and has a multichannel distribution model.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:FPLB has been successfully added to your 